nach oben

Erschienen in:

31.08.2018

Lanosteryl triterpenes from Protorhus longifolia as a cardioprotective agent: a mini review

verfasst von: Nonhlakanipho F. Sangweni, Phiwayinkosi V. Dludla, Rebamang A. Mosa, Abidemi P. Kappo, Andy Opoku, Christo J. F. Muller, Rabia Johnson

Erschienen in: Heart Failure Reviews | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

The epidemic of cardiovascular diseases is a global phenomenon that is exaggerated by the growing prevalence of diabetes mellitus. Coronary artery disease and diabetic cardiomyopathy are the major cardiovascular complications responsible for exacerbated myocardial infarction in diabetic individuals. Increasing research has identified hyperglycemia and hyperlipidemia as key factors driving the augmentation of oxidative stress and a pro-inflammatory response that usually results in increased fibrosis and reduced cardiac efficiency. While current antidiabetic agents remain active in attenuating diabetes-associated complications, overtime, their efficacy proves limited in protecting the hearts of diabetic individuals. This has led to a considerable increase in the number of natural products that are screened for their antidiabetic and cardioprotective properties. These natural products may present essential ameliorative properties relevant to their use as a monotherapy or as an adjunct to current drug agents in combating diabetes and its associated cardiovascular complications. Recent findings have suggested that triterpenes isolated from Protorhus longifolia (Benrh.) Engl., a plant species endemic to Southern Africa, display strong antioxidant and antidiabetic properties that may potentially protect against diabetes-induced cardiovascular complications. Thus, in addition to discussing the pathophysiology associated with diabetes-induced cardiovascular injury, available evidence pertaining to the cardiovascular protective potential of lanosteryl triterpenes from Protorhus longifolia will be discussed.

Baskaran K, Kizar Ahamath B, Radha Shanmugasundaram K, Shanmugasundaram ER (1990) Antidiabetic effect of a leaf extract from Gymnema sylvestre in non-insulin-dependent diabetes mellitus patients. J Ethnopharmacol 30(3):295–300CrossRefPubMed

Manickam M, Ramanathan M, Jahromi MA, Chansouria JP, Ray AB (1997) Antihyperglycemic activity of phenolics from Pterocarpus marsupium. J Nat Prod 60(6):609–610. https://doi.org/10.1021/np9607013 CrossRefPubMed

Sheela CG, Augusti KT (1992) Antidiabetic effects of S-allyl cysteine sulphoxide isolated from garlic Allium sativum Linn. Indian J Exp Biol 30(6):523–526PubMed

Bailey CJ (2017) Metformin: historical overview. Diabetologia 60(9):1566–1576. https://doi.org/10.1007/s00125-017-4318-z CrossRefPubMed

Rios JL, Francini F, Schinella GR (2015) Natural products for the treatment of type 2 diabetes mellitus. Planta Med 81(12–13):975–994. https://doi.org/10.1055/s-0035-1546131 CrossRefPubMed

Rosiak M, Postula M, Kaplon-Cieslicka A, Trzepla E, Czlonkowski A, Filipiak KJ, Opolski G (2013) Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes. Adv Med Sci 58(2):362–368. https://doi.org/10.2478/ams-2013-0009 CrossRefPubMed

Yin M, van der Horst IC, van Melle JP, Qian C, van Gilst WH, Sillje HH, de Boer RA (2011) Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Phys Heart Circ Phys 301(2):H459–H468. https://doi.org/10.1152/ajpheart.00054 CrossRef

Florez H, Pan Q, Ackermann RT, Marrero DG, Barrett-Connor E, Delahanty L, Kriska A, Saudek CD, Goldberg RB, Rubin RR (2012) Impact of lifestyle intervention and metformin on health-related quality of life: the diabetes prevention program randomized trial. J Gen Intern Med 27(12):1594–1601. https://doi.org/10.1007/s11606-012-2122-5 CrossRefPubMedPubMedCentral

Rojas LBA, Gomes MB (2013) Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 5:6. https://doi.org/10.1186/1758-5996-5-6 CrossRefPubMedPubMedCentral

10.

Adeghate E, Kalasz H, Veress G, Tekes K (2010) Medicinal chemistry of drugs used in diabetic cardiomyopathy. Curr Med Chem 17(6):517–551(35). https://doi.org/10.2174/092986710790416281 CrossRefPubMed

11.

Khavandi K, Khavandi A, Asghar O, Greenstein A, Withers S, Anthony M, Heagerty AM, Rayaz A, Malik RA (2009) Diabetic cardiomyopathy—a distinct disease? Best Pract Res Clin Endocrinol Metab 23(3):347–360. https://doi.org/10.1016/j.beem.2008.10.016 CrossRefPubMed

12.

Statistics South Africa (2018) Prevalence of non-communicable dieases. Available at http://www.statssa.gov.za/publications/11025.pdf, Accessed 26 Mar 2018

13.

International Diabetes Federation (2017) International Diabetes Federation diabetes atlas. Eight edition. Accessed 30 Jan 2018

14.

Van Wyk BE (2015) A review of commercially important African medicinal plants. J Ethnopharmacol 176:118–134. https://doi.org/10.1016/j.jep.2015.10.031 CrossRefPubMed

15.

Marnewick JL, Rautenbach F, Venter I, Neethling H, Blackhurst DM, Wolmarans P, Macharia M (2011) Effects of rooibos (Aspalathus linearis) on oxidative stress and biochemical parameters in adults at risk for cardiovascular disease. J Ethnopharmacol 133(1):46–52. https://doi.org/10.1016/j.jep.2010.08.061 CrossRefPubMed

16.

Johnson R, Dludla PV, Ferreira D, Muller CJF, Joubert E (2018) Aspalathin from rooibos (Aspalathus linearis): a bioactive C-glucosyl dihydrochalcone with potential to target the metabolic syndrome. Planta Med 84:568–583. https://doi.org/10.1055/s-0044-100622 CrossRefPubMed

17.

Dludla PV, Joubert E, Muller CJF, Louw J, Johnson R (2017a) Hyperglycemia-induced oxidative stress and heart disease-cardioprotective effects of rooibos flavonoids and phenylpyruvic acid-2-O-beta-D-glucoside. Nutr Metab 14:45. https://doi.org/10.1186/s12986-017-0200-8 CrossRef

18.

Muller CJ, Malherbe CJ, Chellan N, Yagasaki K, Miura Y, Joubert E (2016) Potential of rooibos, its major C-glucosyl flavonoids, and Z-2-(β-D-glucopyranosyloxy)-3-phenylpropenoic acid in prevention of metabolic syndrome. Crit Rev Food Sci Nutr 58(2):227–246. https://doi.org/10.1080/10408398.2016.1157568 CrossRef

19.

Mosa RA, Naidoo JJ, Nkomo FS, Mazibuko SE, Muller CJ, Opoku AR (2014) In vitro antihyperlipidemic potential of triterpenes from stem bark of Protorhus longifolia. Planta Med 80(18):1685–1691. https://doi.org/10.1055/s-0034-1383262 CrossRefPubMed

20.

Mosa RA, Cele NT, Opoku AR (2015) Anticoagulant and anti-inflammatory activity of a triterpene from Protorhus longifolia stem bark. J Med Plant Res 9(19):613–619. https://doi.org/10.5897/JMPR2015.5740 CrossRef

21.

Mosa RA, Cele ND, Mabhida SE, Shabalala SC, Penduka D, Opoku AR (2015) In vivo antihyperglycemic activity of a lanosteryl triterpene from Protorhus longifolia. Molecules 20(7):13374–13383. https://doi.org/10.3390/molecules200713374 CrossRefPubMedPubMedCentral

22.

Putta S, Nagendra SA, Eswar KK, Challa S, Gjumrakch A, Madhihalli BD, Mysore SS, Ramith R, Farhan RZ, Nagendra PMN, Ramakrishna C, Pidugu VR, Yallappa S, Bhadrapura LD (2016) Therapeutic potentials of triterpenes in diabetes and its associated complications. Curr Top Med Chem 16(23):2532–2542(11)CrossRefPubMed

23.

Nazaruk J, Borzym-Kluczyk M (2015) The role of triterpenes in the management of diabetes mellitus and its complications. Phytochem Rev 14(4):675–690. https://doi.org/10.1007/s11101-014-9369-x CrossRefPubMed

24.

Mosa RA, Hlophe NB, Ngema NT, Penduka D, Lawal OA, Opoku AR (2016) Cardioprotective potential of a lanosteryl triterpene from Protorhus longifolia. Pharm Biol 54(12):3244–3248. https://doi.org/10.1080/13880209.2016.1223144 CrossRefPubMed

25.

Machaba KE, Cobongela SZ, Mosa RA, Oladipupo LA, Djarova TG, Opoku AR (2014) In vivo anti-hyperlipidemic activity of the triterpene from the stem bark of Protorhus longifolia (Benrh) Engl. Lipids Health Dis 13:131. https://doi.org/10.1186/1476-511X-13-131 CrossRefPubMedPubMedCentral

26.

Mosa RA, Gwala PE, Oyedeji AO, Opoku AR (2011a) In vitro anti-platelet aggregation, antioxidant and cytotoxic activity of extracts of some Zulu medicinal plants. J Nat Prod 4(2011):136–146

27.

Mosa RA, Shode FO, Singh M, Opoku AR (2011b) Triterpenes from the stem bark of Protorhus longifolia exhibit anti-platelet aggregation activity. Afr J Pharm Pharmacol 5(24):2698–2714. https://doi.org/10.5897/AJPP11.534 CrossRef

28.

World Health Organization (2017) The top 10 causes of death. Available at http://www.who.int/mediacentre/factsheets/fs310/en/. Accessed 31 Jan 2018

29.

Statistics South Africa (2017) Mortality and causes of death, 2015. Available at http://www.statssa.gov.za/publications/P03093/P030932015.pdf, Accessed 30 Jan 2018

30.

Yilmaz S, Canpolat U, Aydogdu S, Abboud HE (2015) Diabetic cardiomyopathy; summary of 41 years. Korean Circ J 45(4):266–272. https://doi.org/10.4070/kcj.2015.45.4.266 CrossRefPubMedPubMedCentral

31.

Dandamudi S, Slusser J, Mahoney DW, Redfield MM, Rodeheffer RJ, Chen HH (2014) The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota. J Card Fail 20(5):304–309. https://doi.org/10.1016/j.cardfail.2014.02.007 CrossRefPubMedPubMedCentral

32.

Aronson D, Edelman ER (2014) Coronary artery disease and diabetes mellitus. Cardiol Clin 32(3):439–455. https://doi.org/10.1016/j.ccl.2014.04.001 CrossRefPubMedPubMedCentral

33.

Boudina S, Abel ED (2007) Diabetic cardiomyopathy revisited. Circulation 115(25):3213–3223. https://doi.org/10.1161/CIRCULATIONAHA.106.679597 CrossRefPubMed

34.

Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, Aziz S, Johnson JI, Bugger H, Zaha VG, Abel ED (2007) Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 56(10):2457–2466. https://doi.org/10.2337/db07-0481 CrossRefPubMed

35.

Ansley DM, Wang B (2013) Oxidative stress and myocardial injury in the diabetic heart. J Pathol 229(2):232–241. https://doi.org/10.1002/path.4113 CrossRefPubMedPubMedCentral

36.

Loganathan R, Bilgen M, Al-Hafez B, Alenezy MD, Smirnova IV (2006) Cardiac dysfunction in the diabetic rat: quantitative evaluation using high resolution magnetic resonance imaging. Cardiovasc Diabetol 5(7):7. https://doi.org/10.1186/1475-2840-5-7 CrossRefPubMedPubMedCentral

37.

Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ (2002) Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 51(6):1938–1948CrossRefPubMed

38.

Marfella R, Di Filippo C, Portoghese M, Barbieri M, Ferraraccio F, Siniscalchi M, Cacciapuoti F, Rossi F, D’Amico M, Paolisso G (2009) Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome. J Lipid Res 50(11):2314–2323. https://doi.org/10.1194/jlr.P900032-JLR200 CrossRefPubMedPubMedCentral

39.

Garg R, Aggarwal S, Kumar R, Sharma G (2015) Association of atherosclerosis with dyslipidemia and co-morbid conditions: a descriptive study. J Nat Sci Biol Med 6(1):163–168. https://doi.org/10.4103/0976-9668.149117 CrossRefPubMedPubMedCentral

40.

Miller M (2009) Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM 102(9):657–667. https://doi.org/10.1093/qjmed/hcp065 CrossRefPubMedPubMedCentral

41.

Kengne AP, Dzudie A, Sobngwi E (2008) Heart failure in sub-Saharan Africa: a literature review with emphasis on individuals with diabetes. Vasc Health Risk Manag 4(1):123–130CrossRefPubMedPubMedCentral

42.

Nigro G, Comi LI, Politano L, Bain RJ (1990) The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 26(3):271–277CrossRefPubMed

43.

Boudina S, Abel ED (2010) Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 11(1):31–39. https://doi.org/10.1007/s11154-010-9131-7 CrossRefPubMedPubMedCentral

44.

Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30(6):595–602CrossRefPubMed

45.

Lionetti V, Stanley WC, Recchia FA (2011) Modulating fatty acid oxidation in heart failure. Cardiovasc Res 90(2):202–209. https://doi.org/10.1093/cvr/cvr038 CrossRefPubMedPubMedCentral

46.

Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC (2010) Myocardial fatty acid metabolism in health and disease. Physiol Rev 90(1):207–258. https://doi.org/10.1152/physrev.00015.2009 CrossRefPubMed

47.

Randle PJ, Garland PB, Hales CN, Newsholme EA (1963) The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1(7285):785–789CrossRefPubMed

48.

Johnson R, Dludla P, Joubert E, February F, Mazibuko S, Ghoor S, Muller C, Louw J (2016) Aspalathin, a dihydrochalcone C-glucoside, protects H9c2 cardiomyocytes against high glucose induced shifts in substrate preference and apoptosis. Mol Nutr Food Res 60(4):922–934. https://doi.org/10.1002/mnfr.201500656 CrossRefPubMed

49.

Long YC, Zierath JR (2006) AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 116(7):1776–1783. https://doi.org/10.1172/jci29044 CrossRefPubMedPubMedCentral

50.

Tsai JY, Villegas-Montoya C, Boland BB, Blasier Z, Egbejimi O, Gonzalez R, Kueht M, McElfresh TA, Brewer RA, Chandler MP, Bray MS, Young ME (2013) Influence of dark phase restricted high fat feeding on myocardial adaptation in mice. J Mol Cell Cardiol 55:147–155. https://doi.org/10.1016/j.yjmcc.2012.09.010 CrossRefPubMed

51.

Bugger H, Abel ED (2014) Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 57(4):660–671. https://doi.org/10.1007/s00125-014-3171-6 CrossRefPubMedPubMedCentral

52.

Taegtmeyer H, McNulty P, Young ME (2002) Adaptation and maladaptation of the heart in diabetes: part I: general concepts. Circulation 105(14):1727–1733CrossRefPubMed

53.

Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, Lopez-Otin C, Lugli E, Madeo F, Malorni W, Marine JC, Martin SJ, Martinou JC, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Munoz-Pinedo C, Nunez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon HU, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovsky B, Melino G, Kroemer G (2015) Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 22(1):58–73. https://doi.org/10.1038/cdd.2014.137 CrossRefPubMed

54.

Bo H, Jiang N, Ma G, Qu J, Zhang G, Cao D, Wen L, Liu S, Ji LL, Zhang Y (2008) Regulation of mitochondrial uncoupling respiration during exercise in rat heart: role of reactive oxygen species (ROS) and uncoupling protein 2. Free Radic Biol Med 44(7):1373–1381. https://doi.org/10.1016/j.freeradbiomed.2007.12.033 CrossRefPubMed

55.

Boehm EA, Jones BE, Radda GK, Veech RL, Clarke K (2001) Increased uncoupling proteins and decreased efficiency in palmitate-perfused hyperthyroid rat heart. Am J Phys Heart Circ Phys 280(3):H977–H983

56.

Dludla PV, Muller CJ, Joubert E, Louw J, Essop MF, Gabuza KB, Ghoor S, Huisamen B, Johnson R (2017b) Aspalathin protects the heart against hyperglycemia-induced oxidative damage by up-regulating Nrf2 expression. Molecules 22(1). https://doi.org/10.3390/molecules22010129

57.

Johnson R, Dludla PV, Muller CJ, Huisamen B, Essop MF, Louw J (2017) The transcription profile unveils the cardioprotective effect of aspalathin against lipid toxicity in an in vitro H9c2 model. Molecules 22(2). https://doi.org/10.3390/molecules22020219

58.

He X, Kan H, Cai L, Ma Q (2009) Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes. J Mol Cell Cardiol 46(1):47–58. https://doi.org/10.1016/j.yjmcc.2008.10.007 CrossRefPubMed

59.

Satta SMA, Wilkinson FL, Alexander MY, White S (2017) The role of Nrf2 in cardiovascular function and disease. Oxidative medicine and cellular longevity. Oxidative Med Cell Longev 2017:18. https://doi.org/10.1155/2017/9237263 CrossRef

60.

An J, Chen Y, Huang Z (2004) Critical upstream signals of cytochrome C release induced by a novel Bcl-2 inhibitor. J Biol Chem 279(18):19133–19140. https://doi.org/10.1074/jbc.M400295200 CrossRefPubMed

61.

Cicek FA, Toy A, Tuncay E, Can B, Turan B (2014) Beta-blocker timolol alleviates hyperglycemia-induced cardiac damage via inhibition of endoplasmic reticulum stress. J Bioenerg Biomembr 46(5):377–387. https://doi.org/10.1007/s10863-014-9568-6 CrossRefPubMed

62.

Dludla PV, Muller CJ, Joubert E, Louw J, Gabuza KB, Huisamen B, Essop MF, Johnson R (2016) Phenylpyruvic Acid-2-O-beta-D-glucoside attenuates high glucose-induced apoptosis in H9c2 cardiomyocytes. Planta Med 82(17):1468–1474. https://doi.org/10.1055/s-0042-110856 CrossRefPubMed

63.

Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35(4):495–516. https://doi.org/10.1080/01926230701320337 CrossRefPubMedPubMedCentral

64.

Crompton M (1999) The mitochondrial permeability transition pore and its role in cell death. Biochem J 341(Pt 2):233–249CrossRefPubMedPubMedCentral

65.

Gupta SK, Dongare S, Mathur R, Mohanty IR, Srivastava S, Mathur S, Nag TC (2015) Genistein ameliorates cardiac inflammation and oxidative stress in streptozotocin-induced diabetic cardiomyopathy in rats. Mol Cell Biochem 408(1–2):63–72. https://doi.org/10.1007/s11010-015-2483-2 CrossRefPubMed

66.

Suzuki H, Kayama Y, Sakamoto M, Iuchi H, Shimizu I, Yoshino T, Katoh D, Nagoshi T, Tojo K, Minamino T, Yoshimura M, Utsunomiya K (2015) Arachidonate 12/15-lipoxygenase-induced inflammation and oxidative stress are involved in the development of diabetic cardiomyopathy. Diabetes 64(2):618–630. https://doi.org/10.2337/db13-1896 CrossRefPubMed

67.

Suthahar N, Meijers WC, Brouwers FP, Heerspink HJL, Gansevoort RT, van der Harst P, Bakker SJL, de Boer RA (2018) Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population. Int J Cardiol 250:188–194. https://doi.org/10.1016/j.ijcard.2017.10.035 CrossRefPubMed

68.

Battiprolu PK, Gillette TG, Wang ZV, Lavandero S, Hill JA (2010) Diabetic cardiomyopathy: mechanisms and therapeutic targets. Drug Discov Today Dis Mech 7(2):e135–e143. https://doi.org/10.1016/j.ddmec.2010.08.001 CrossRefPubMedPubMedCentral

69.

Fang WJ, Wang CJ, He Y, Zhou YL, Peng XD, Liu SK (2017) Resveratrol alleviates diabetic cardiomyopathy in rats by improving mitochondrial function through PGC-1alpha deacetylation. Acta Pharmacol Sin 39:59–73. https://doi.org/10.1038/aps.2017.50 CrossRefPubMedPubMedCentral

70.

Guimaraes JF, Muzio BP, Rosa CM, Nascimento AF, Sugizaki MM, Fernandes AA, Cicogna AC, Padovani CR, Okoshi MP, Okoshi K (2015) Rutin administration attenuates myocardial dysfunction in diabetic rats. Cardiovasc Diabetol 14:90. https://doi.org/10.1186/s12933-015-0255-7 CrossRefPubMedPubMedCentral

71.

Chen WJ, Greulich S, van der Meer RW, Rijzewijk LJ, Lamb HJ, de Roos A, Smit JW, Romijn JA, Ruige JB, Lammertsma AA, Lubberink M, Diamant M, Ouwens DM (2013) Activin A is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes. Cardiovasc Diabetol 12:150. https://doi.org/10.1186/1475-2840-12-150 CrossRefPubMedPubMedCentral

72.

Sun X, Chen RC, Yang ZH, Sun GB, Wang M, Ma XJ, Yang LJ, Sun XB (2014) Taxifolin prevents diabetic cardiomyopathy in vivo and in vitro by inhibition of oxidative stress and cell apoptosis. Food Chem Toxicol 63:221–232. https://doi.org/10.1016/j.fct.2013.11.013 CrossRefPubMed

73.

Liu X, Zhu L, Tan J, Zhou X, Xiao L, Yang X, Wang B (2014) Glucosidase inhibitory activity and antioxidant activity of flavonoid compound and triterpenoid compound from Agrimonia Pilosa Ledeb. BMC Complement Altern Med 14:12. https://doi.org/10.1186/1472-6882-14-12 CrossRefPubMedPubMedCentral

74.

Yang Y, Li C, Xiang X, Dai Z, Chang J, Zhang M, Cai H, Zhang H, Zhang M, Guo Y, Wu Z (2014) Ursolic acid prevents endoplasmic reticulum stress-mediated apoptosis induced by heat stress in mouse cardiac myocytes. J Mol Cell Cardiol 67:103–111. https://doi.org/10.1016/j.yjmcc.2013.12.018 CrossRefPubMed

75.

Hamid K, Ng I, Tallapragada VJ, Varadi L, Hibbs DE, Hanrahan J, Groundwater PW (2016) An investigation of the differential effects of ursane triterpenoids from Centella asiatica, and their semisynthetic analogues, on GABAA receptors. Chem Biol Drug Des 88(3):386–397. https://doi.org/10.1111/cbdd.12766 CrossRefPubMed

76.

Rodriguez-Rodriguez R (2015) Oleanolic acid and related triterpenoids from olives on vascular function: molecular mechanisms and therapeutic perspectives. Curr Med Chem 22(11):1414–1425CrossRefPubMed

77.

Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, Grossman EB, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J, Warnock DG (2011) Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365(4):327–336. https://doi.org/10.1056/NEJMoa1105351 CrossRefPubMed

78.

Sidjui LS, Eyong KO, Hull KG (2017) Bioactive seco-lanostane-type triterpenoids from the roots of Leplaea mayombensis. J Nat Prod 80(10):2644–2651. https://doi.org/10.1021/acs.jnatprod.7b00210

79.

Hill RA, Connolly JD (2017) Triterpenoids. Nat Prod Rep 34(1):90–122. https://doi.org/10.1039/c6np00094 CrossRefPubMed

80.

Lee I, Kim J, Ryoo I, Kim Y, Choo S, Yoo I, Min B, Na M, Hattori M, Bae K (2010a) Lanostane triterpenes from Ganoderma lucidum suppress the adipogenesis in 3T3-L1 cells through down-regulation of SREBP-1c. Bioorg Med Chem Lett 20(18):5577–5581. https://doi.org/10.1016/j.bmcl.2010.06.093 CrossRefPubMed

81.

Lee I, Seo J, Kim J, Kim H, Youn U, Lee J, Jung H, Na M, Hattori M, Min B, Bae K (2010b) Lanostane triterpenes from the fruiting bodies of Ganoderma lucidum and their inhibitory effects on adipocyte differentiation in 3T3-L1 cells. J Nat Prod 73(2):172–176. https://doi.org/10.1021/np900578h CrossRefPubMed

82.

Dold AP, Cocks ML (2002) The trade in medicinal plants in the Eastern Cape Province, South Africa. S Afr J Sci 98(11–12):589–597

83.

Keirungi J, Fabricius C (2005) Selecting medicinal plants for cultivation at Nqabara on the Eastern Cape Wild Coast, South Africa. S Afr J Sci 101(11–12):497–501 doi: 10520/EJC96329

84.

Lawson K (2015) Botanical and plant-derived drugs: global markets, BIO022G. Available at: https://www.bccresearch.com/market-research/biotechnology/botanical-plant-derived-drugs-report-bio022g

85.

Joubert EDBD (2011) Rooibos (Aspalathus linearis) beyond the farm gate: from herbal tea to potential phytopharmaceutical. S Afr J Bot 77(4):869–886. https://doi.org/10.1016/j.sajb.2011.07.004 CrossRef

86.

Suleiman MM, McGaw LI, Naidoo V, Eloff J (2009) Detection of antimicrobial compounds by bioautography of different extracts of leaves of selected South African tree species. Afr J Tradit Complement Altern Med 7(1). https://doi.org/10.4314/57269

87.

Penduka D, Mosa R, Simelane M, Basson A, Okoh A, Opoku A (2014) Evaluation of the anti-Listeria potentials of some plant-derived triterpenes. Ann Clin Microbiol Antimicrob 13:37. https://doi.org/10.1186/s12941-014-0037-1 CrossRefPubMedPubMedCentral

88.

Sellers RS, Radi ZA, Khan NK (2010) Pathophysiology of cyclooxygenases in cardiovascular homeostasis. Vet Pathol 47(4):601–613. https://doi.org/10.1177/0300985810364389 CrossRefPubMed

89.

Kunutsor SK, Apekey TA, Khan H (2014) Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies. Atherosclerosis 236(1):7–17. https://doi.org/10.1016/j.atherosclerosis.2014.06.006 CrossRefPubMed

90.

Zhou R, Xu Q, Zheng P, Yan L, Zheng J, Dai G (2008) Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat. Eur J Pharmacol 586(1):244–250. https://doi.org/10.1016/j.ejphar.2008.02.057 CrossRefPubMed

91.

Mabhida SE, Mosa RA, Penduka D, Osunsanmi FO, Dludla PV, Tryana G, Djarova TG, Opuko AR (2017) A lanosteryl triterpene from Protorhus longifolia improves glucose tolerance and pancreatic beta cell ultrastructure in type 2 diabetic rats. Molecules 22(8):1252. https://doi.org/10.3390/molecules22081252 CrossRefPubMedCentral

Titel: Lanosteryl triterpenes from Protorhus longifolia as a cardioprotective agent: a mini review
verfasst von: Nonhlakanipho F. Sangweni
Phiwayinkosi V. Dludla
Rebamang A. Mosa
Abidemi P. Kappo
Andy Opoku
Christo J. F. Muller
Rabia Johnson
Publikationsdatum: 31.08.2018
Verlag: Springer US
Erschienen in: Heart Failure Reviews / Ausgabe 1/2019
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-018-9733-9

Neu im Fachgebiet Kardiologie

23.04.2024 | Ablationstherapie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Lanosteryl triterpenes from Protorhus longifolia as a cardioprotective agent: a mini review

Abstract

Neu im Fachgebiet Kardiologie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Kardiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Loop diuretics in chronic heart failure: how to manage congestion?

Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology

Intercalated discs: cellular adhesion and signaling in heart health and diseases

The effect of influenza vaccination on mortality and hospitalization in patients with heart failure: a systematic review and meta-analysis

Continuous versus intermittent administration of furosemide in acute decompensated heart failure: a systematic review and meta-analysis

Metabolic remodeling of substrate utilization during heart failure progression

Neu im Fachgebiet Kardiologie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Kardiologie